

Express Mail: EV 630723817 US  
USSN: 10/749,907  
Attorney Docket: I-2002.028 US C1  
Response to Office Action of November 2, 2005

**Amendments to the Claims:**

1. (Currently Amended) A method of propagating an avian reovirus, ~~belonging to an antigenic class of avian reovirus ERS isolates, on Vero cells, without prior adaptation, comprising the steps of:~~

a. inoculating a Vero cell with the avian reovirus without prior adaptation, wherein the avian reovirus belongs to an antigenic class of avian reovirus ERS isolates that

i) is able to induce antiserum in an animal, which antiserum causes a reduction of the plaques formed by avian reovirus ERS, a sample of which is deposited at the ECACC under accession no. 99011475, of at least 75% in a plaque reduction assay, and

ii) wherein the avian reovirus positively reacts with polyclonal avian reovirus antiserum but not with monoclonal antibodies identified by accessions nos. 99011472, 99011473 and 99011474, samples of which are deposited at the ECACC [[ECAC,]] comprising the steps of:

a. inoculating a Vero cell with the avian reovirus;  
b. allowing the avian reovirus to multiply to a titer of at least about 3.0 TCID<sub>50</sub>/ml;  
and,  
c. harvesting the avian reovirus.

2. (Cancelled)

Express Mail: EV 630723817 US  
USSN: 10/749,907  
Attorney Docket: I-2002.028 US C1  
Response to Office Action of November 2, 2005

3. (Cancelled)
4. (previously presented) The method of Claim 1 wherein the titer is at least about 4.0 TCID<sub>50</sub>/ml.
5. (previously presented) The method of Claim 1 3 wherein the titer is at least about 5.1 TCID<sub>50</sub>/ml.
6. (currently amended) The method of Claim 1 wherein the titer is at least about 5.3 TCID<sub>50</sub>/ml.
7. (Cancelled)
8. (Cancelled)
9. (previously presented) The method of Claim 1 further comprising the step of administering the reovirus with a pharmaceutically acceptable carrier or diluent to an organism, as an immunogenic composition or vaccine.
10. (Original) The method of Claim 9 wherein the reovirus is either live, attenuated or killed.

Express Mail: EV 630723817 US  
USSN: 10/749,907  
Attorney Docket: I-2002.028 US C1  
Response to Office Action of November 2, 2005

11. (Original) The method of Claim 9 wherein the immunogenic composition and/or vaccine further comprises at least one of Marek's Disease Virus, Infectious Bursal Disease Virus, Newcastle Disease Virus, Infectious Bronchitis Virus, Avian Encephalomyelitis Virus, Fowl Pox Virus, and Chicken Anemia Agent.

12. (Cancelled)

13. (Original) The method of Claim 1 wherein the reovirus is naturally non-pathogenic.

14. (Original) The method of Claim 1 wherein the reovirus is isolated from the neurological system.

15. (Original) The method of Claim 14 wherein the neurological system consists of brain, spinal chord, and/or other structures associated with the neurological system.

16. (Original) The method of Claim 14 wherein the reovirus is isolated from a chicken.

Claims 17-20 (Cancelled)